Ucb SA
XBRU:UCB

Watchlist Manager
Ucb SA Logo
Ucb SA
XBRU:UCB
Watchlist
Price: 189.4 EUR -1.17% Market Closed
Market Cap: 35.9B EUR
Have any thoughts about
Ucb SA?
Write Note

P/E
Price to Earnings

149.7
Current
38.3
Median
21.8
Industry
Higher than median
Higher than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
149.7
=
Market Cap
35.9B EUR
/
Net Income
240m EUR
All Countries
Close
Market Cap P/E
BE
Ucb SA
XBRU:UCB
35.9B EUR 149.7
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY -5 347 888.9
US
Eli Lilly and Co
NYSE:LLY
757B USD 90
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP -15 783.5
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 29
US
Johnson & Johnson
NYSE:JNJ
350.9B USD 24
US
Merck & Co Inc
NYSE:MRK
252.8B USD 20.7
CH
Roche Holding AG
SIX:ROG
200.1B CHF 17.4
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 31.6
CH
Novartis AG
SIX:NOVN
171.5B CHF 10.8
US
Pfizer Inc
NYSE:PFE
150.9B USD 35.5
Earnings Growth P/E to Growth
BE
Ucb SA
XBRU:UCB
Average P/E: 45.4
149.7
399%
0.4
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
90
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
24
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.4
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.6
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.5
719%
0

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
44.3
2-Years Forward
P/E
27.9
3-Years Forward
P/E
21

See Also

Discover More